The warrant restructuring provides near-term cash but at the cost of substantial dilution and a lower effective strike price, signaling financial strain. Monitor stockholder vote on new warrant shares and any subsequent cash burn updates. The ~$2M raise is modest for a clinical-stage biotech; further capital needs are likely.
Price Chart
Executive Summary
Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proceeds by reducing the exercise price on 1.17M existing warrants from $3.50 to $1.73 per share, plus issuing new short-term warrants for up to 2.34M additional shares at $1.73. The transaction provides near-term cash but adds significant potential dilution (up to ~3.5M new shares vs. current market cap of $26M), and the new warrants require stockholder approval before exercisability.
Key Financial Metrics
Key Facts
- Definitive agreement to exercise 1,172,414 existing warrants at reduced exercise price of $1.73/share (original $3.50), generating ~$2M gross proceeds.
- Company will issue new unregistered short-term warrants to purchase up to 2,344,828 shares at $1.73, exercisable upon stockholder approval and expiring 2 years from issuance.
- Potential additional gross proceeds of ~$4M if new warrants are fully exercised on a cash basis.
- H.C. Wainwright acting as exclusive placement agent.
- Proceeds used for working capital and general corporate purposes.
- Current market cap is $26M; total potential dilution from both warrant tranches is ~3.5M shares (significant relative to current float).
Financial Impact
Immediate ~$2M gross proceeds from existing warrant exercise; potential ~$4M additional from new warrants; total potential dilution of ~3.5M shares against $26M market cap.
Risk Factors
- Stockholder approval may not be obtained for new warrant shares, limiting upside from that tranche.
- Dilution from up to 3.5M new shares could pressure stock price.
- Company remains a clinical-stage biotech with no approved products; cash runway extension is limited.
- Forward-looking statements highlight going-concern risk and need for additional capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303540 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | awaiting T+20 | $0.5110 (−0.16%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | awaiting T+20 | $0.5110 (−3.26%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | awaiting T+20 | $0.5110 (−3.26%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | awaiting T+20 | $0.5110 (−11.32%) |
Oct 2, 2026 26d ago | EFFECT | $0.8112 | awaiting T+20 | awaiting T+20 | $0.5110 (+37.01%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5110 (+38.55%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5110 (−47.21%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5110 (+37.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers